Hutchmed China Ltd (Hutchmed), formerly Hutchison China MediTech Ltd, focuses on the discovery, development, and commercialization of targeted therapies for cancer and immunological diseases. The company manufactures pharmaceuticals and health-related consumer products and sells them in China (PRC) and Hong Kong.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Hutchmed’s research and development (R&D) focuses on developing and advancing its pipeline of novel oral drug candidates for cancer and immunological diseases. In FY2022, Hutchmed incurred expenses of US$386.9 million on R&D activities which grew by 90.7% YoY. The company’s pipeline includes savolitinib, a selective mesenchymal epithelial transition factor (MET) inhibitor in late-stage clinical development as a monotherapy and as a combination therapy for the treatment of non-small cell lung cancer (NSCLC) and gastric cancer. It is advancing savolitinib in partnership with AstraZeneca. It is investigating fruquintinib, a selective inhibitor of VEGFR 1, 2 and 3 for the treatment of various types of solid tumors including colorectal cancer, NSCLC, gastric cancer and lung cancer, others. The company is evaluating surufatinib, an angio-immuno kinase inhibitor for the treatment of solid tumors including lung cancer, gastric cancer, kidney cancer, and prostate cancer. It is also advancing Surufatinib as a potential treatment for neuroendocrine tumors, biliary tract cancer and soft-tissue sarcoma. It is investigating Sovleplenib (HMPL-523), a selective Syk inhibitor for the treatment of rheumatoid arthritis and haematological cancers. Amdizalisib (HMPL-689), a highly selective and potent small molecule inhibitor targeting the isoform phosphoinositide 3’-kinase delta (PI3Kd) for Phase I/Ib for the treatment of advanced relapsed or refractory lymphoma; HMPL-453, a FGFR ½/3 inhibitor for treatment of solid tumors; HMPL-306, a small molecule, isocitrate dehydrogenase (IDH) 1 and 2 inhibitor in preclinical phase for the treatment of solid tumors, hematological malignancies and gliomas; HMPL-295, a novel ERK inhibitor for the treatment of solid tumors; Epitinib, a EGFR inhibitor in preclinical for the treatment of NSCLC; HMPL-653 for solid tumors and HMPL-760 for B-Cell NHL. The company’s pipeline covering the therapeutic areas including MET, VEGFR, FGFR, CSF-1R, PIEKO, Syk, EZH2, IDH, ERK, BTK, CD47 and EGFR. As of December 31, 2022 the company held 232 issued patents, which included 18 patents in China, 22 patents in the US and 12 patents in Europe. It also had 295 patent applications pending in China, America and Europe, and seven pending Patent Cooperation Treaty related to the drug candidates based on its technology platform.